• Explore /
  • Poster
  • / Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).

Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).

Abstract Poster

Authors

Kohei Shitara

Kohei Shitara

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Kohei Shitara , Rui-Hua Xu , Diarmuid Martin Moran , Abraham Guerrero , Ran Li , Janet Pavese , Maria Matsangou , Pranob P. Bhattacharya , Jaffer A. Ajani , Manish A. Shah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03504397, NCT03653507

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4035)

DOI

10.1200/JCO.2023.41.16_suppl.4035

Abstract #

4035

Poster Bd #

356

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Manish A. Shah

First Author: Keun-Wook Lee

First Author: Manish A. Shah